US Patent

US9757406 — Combination formulation of two antiviral compounds

Formulation · Assigned to Gilead Pharmasset LLC · Expires 2034-01-30 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical composition combining Compound I with substantially crystalline sofosbuvir.

USPTO Abstract

Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number: US9757406
Jurisdiction: US
Classification: Formulation
Expires: 2034-01-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.